IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0250634.html
   My bibliography  Save this article

Association of SMAD4 loss with drug resistance in clinical cancer patients: A systematic meta-analysis

Author

Listed:
  • Wei Xu
  • Sau Har Lee
  • Fengjun Qiu
  • Li Zhou
  • Xiaoling Wang
  • Tingjie Ye
  • Xudong Hu

Abstract

Background: Drug resistance frequently led to the failure of chemotherapy for malignant cancers, hence causing cancer relapse. Thus, understanding mechanism of drug resistance in cancer is vital to improve the treatment efficacy. Here, we aim to evaluate the association between SMAD4 expression and the drug resistance in cancers by performing a meta-analysis. Method: Relevant studies detecting SMAD4 expression in cancer patients treated with chemo-drugs up till December 2020 were systematically searched in four common scientific databases using selected keywords. The pooled hazard ratio (HR) was the ratio of hazard rate between SMAD4neg population vs SMAD4pos population. The HRs and risk ratios (RRs) with 95% confidence intervals (CIs) were used to explore the association between SMAD4 expression losses with drug resistance in cancers. Result: After an initial screening according to the inclusion and exclusion criteria, eleven studies were included in the meta-analysis. There were a total of 2092 patients from all the included studies in this analysis. Results obtained indicated that loss of SMAD4 expression was significantly correlated with drug resistance with pooled HRs (95% CI) of 1.23 (1.01–1.45), metastasis with pooled RRs (95% CI) of 1.10 (0.97–1.25) and recurrence with pooled RRs (95% CI) of 1.32 (1.06–1.64). In the subgroup analysis, cancer type, drug type, sample size and antibody brand did not affect the significance of association between loss of SMAD4 expression and drug resistance. In addition, there was no evidence of publication bias as suggested by Begg’s test. Conclusion: Findings from our meta-analysis demonstrated that loss of SMAD4 expression was correlated with drug resistance, metastasis and recurrence. Therefore, SMAD4 expression could be potentially used as a molecular marker for cancer resistance.

Suggested Citation

  • Wei Xu & Sau Har Lee & Fengjun Qiu & Li Zhou & Xiaoling Wang & Tingjie Ye & Xudong Hu, 2021. "Association of SMAD4 loss with drug resistance in clinical cancer patients: A systematic meta-analysis," PLOS ONE, Public Library of Science, vol. 16(5), pages 1-14, May.
  • Handle: RePEc:plo:pone00:0250634
    DOI: 10.1371/journal.pone.0250634
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0250634
    Download Restriction: no

    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0250634&type=printable
    Download Restriction: no

    File URL: https://libkey.io/10.1371/journal.pone.0250634?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Yiping Du & Xin Zhou & Zebo Huang & Tianzhu Qiu & Jian Wang & Wei Zhu & Tongshan Wang & Ping Liu, 2014. "Meta-Analysis of the Prognostic Value of Smad4 Immunohistochemistry in Various Cancers," PLOS ONE, Public Library of Science, vol. 9(10), pages 1-10, October.
    2. Philip Haywood & Johan Raad & Kees Gool & Marion Haas & Gisselle Gallego & Sallie-Anne Pearson & Margaret Faedo & Robyn Ward, 2012. "Chemotherapy Administration," PharmacoEconomics, Springer, vol. 30(12), pages 1173-1186, December.
      • Philip Haywood & Johan Raad & Kees Gool & Marion Haas & Gisselle Gallego & Sallie-Anne Pearson & Margaret Faedo & Robyn Ward, 2012. "Chemotherapy Administration," PharmacoEconomics, Springer, vol. 30(12), pages 1173-1186, December.
    3. Neil Vasan & José Baselga & David M. Hyman, 2019. "A view on drug resistance in cancer," Nature, Nature, vol. 575(7782), pages 299-309, November.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Heathcliff Dorado García & Fabian Pusch & Yi Bei & Jennifer Stebut & Glorymar Ibáñez & Kristina Guillan & Koshi Imami & Dennis Gürgen & Jana Rolff & Konstantin Helmsauer & Stephanie Meyer-Liesener & N, 2022. "Therapeutic targeting of ATR in alveolar rhabdomyosarcoma," Nature Communications, Nature, vol. 13(1), pages 1-15, December.
    2. Xiaoting Sun & Wenhai Sui & Zepeng Mu & Sisi Xie & Jinxiu Deng & Sen Li & Takahiro Seki & Jieyu Wu & Xu Jing & Xingkang He & Yangang Wang & Xiaokun Li & Yunlong Yang & Ping Huang & Minghua Ge & Yihai , 2023. "Mirabegron displays anticancer effects by globally browning adipose tissues," Nature Communications, Nature, vol. 14(1), pages 1-13, December.
    3. Shigekazu Murakami & Shannon M. White & Alec T. McIntosh & Chan D. K. Nguyen & Chunling Yi, 2023. "Spontaneously evolved progenitor niches escape Yap oncogene addiction in advanced pancreatic ductal adenocarcinomas," Nature Communications, Nature, vol. 14(1), pages 1-20, December.
    4. Anna Gogleva & Dimitris Polychronopoulos & Matthias Pfeifer & Vladimir Poroshin & Michaël Ughetto & Matthew J. Martin & Hannah Thorpe & Aurelie Bornot & Paul D. Smith & Ben Sidders & Jonathan R. Dry &, 2022. "Knowledge graph-based recommendation framework identifies drivers of resistance in EGFR mutant non-small cell lung cancer," Nature Communications, Nature, vol. 13(1), pages 1-14, December.
    5. Weili Wang & Huizhen Zheng & Jun Jiang & Zhi Li & Dongpeng Jiang & Xiangru Shi & Hui Wang & Jie Jiang & Qianqian Xie & Meng Gao & Jianhong Chu & Xiaoming Cai & Tian Xia & Ruibin Li, 2022. "Engineering micro oxygen factories to slow tumour progression via hyperoxic microenvironments," Nature Communications, Nature, vol. 13(1), pages 1-17, December.
    6. Tom Nyen & Mélanie Planque & Lilian Wagensveld & Joao A. G. Duarte & Esther A. Zaal & Ali Talebi & Matteo Rossi & Pierre-René Körner & Lara Rizzotto & Stijn Moens & Wout Wispelaere & Regina E. M. Baid, 2022. "Serine metabolism remodeling after platinum-based chemotherapy identifies vulnerabilities in a subgroup of resistant ovarian cancers," Nature Communications, Nature, vol. 13(1), pages 1-19, December.
    7. Rong Cai & Chiagoziem Ngwadom & Ravindra Saxena & Jayashree Soman & Chase Bruggeman & David P. Hickey & Rafael Verduzco & Caroline M. Ajo-Franklin, 2024. "Creation of a point-of-care therapeutics sensor using protein engineering, electrochemical sensing and electronic integration," Nature Communications, Nature, vol. 15(1), pages 1-11, December.
    8. Anastasia Samarkina & Markus Kirolos Youssef & Paola Ostano & Soumitra Ghosh & Min Ma & Beatrice Tassone & Tatiana Proust & Giovanna Chiorino & Mitchell P. Levesque & Sandro Goruppi & Gian Paolo Dotto, 2023. "Androgen receptor is a determinant of melanoma targeted drug resistance," Nature Communications, Nature, vol. 14(1), pages 1-19, December.
    9. Weier Bao & Ming Liu & Jiaqi Meng & Siyuan Liu & Shuang Wang & Rongrong Jia & Yugang Wang & Guanghui Ma & Wei Wei & Zhiyuan Tian, 2021. "MOFs-based nanoagent enables dual mitochondrial damage in synergistic antitumor therapy via oxidative stress and calcium overload," Nature Communications, Nature, vol. 12(1), pages 1-17, December.
    10. Maria Kleshnina & Sabrina Streipert & Joel S. Brown & Kateřina Staňková, 2023. "Game Theory for Managing Evolving Systems: Challenges and Opportunities of Including Vector-Valued Strategies and Life-History Traits," Dynamic Games and Applications, Springer, vol. 13(4), pages 1130-1155, December.
    11. Irati Macaya & Marta Roman & Connor Welch & Rodrigo Entrialgo-Cadierno & Marina Salmon & Alba Santos & Iker Feliu & Joanna Kovalski & Ines Lopez & Maria Rodriguez-Remirez & Sara Palomino-Echeverria & , 2023. "Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer," Nature Communications, Nature, vol. 14(1), pages 1-19, December.
    12. Yanmei Zhang & Qifan Hu & Yuquan Pei & Hao Luo & Zixuan Wang & Xinxin Xu & Qing Zhang & Jianli Dai & Qianqian Wang & Zilian Fan & Yongcong Fang & Min Ye & Binhan Li & Mailin Chen & Qi Xue & Qingfeng Z, 2024. "A patient-specific lung cancer assembloid model with heterogeneous tumor microenvironments," Nature Communications, Nature, vol. 15(1), pages 1-17, December.
    13. Dongzhe Wu & Xiaolin Gao & Yongjin Shi & Hao Wang & Wendi Wang & Yanbin Li & Zicheng Zheng, 2022. "Association between Handgrip Strength and the Systemic Immune-Inflammation Index: A Nationwide Study, NHANES 2011–2014," IJERPH, MDPI, vol. 19(20), pages 1-12, October.
    14. Chunge Zhong & Wen-Jie Jiang & Yingjia Yao & Zexu Li & You Li & Shengnan Wang & Xiaofeng Wang & Wenjuan Zhu & Siqi Wu & Jing Wang & Shuangshuang Fan & Shixin Ma & Yeshu Liu & Han Zhang & Wenchang Zhao, 2024. "CRISPR screens reveal convergent targeting strategies against evolutionarily distinct chemoresistance in cancer," Nature Communications, Nature, vol. 15(1), pages 1-21, December.
    15. Jorge Gómez Tejeda Zañudo & Romualdo Barroso-Sousa & Esha Jain & Qingchun Jin & Tianyu Li & Jorge E. Buendia-Buendia & Alyssa Pereslete & Daniel L. Abravanel & Arlindo R. Ferreira & Eileen Wrabel & Ka, 2024. "Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial," Nature Communications, Nature, vol. 15(1), pages 1-19, December.
    16. Gursharan K. Sohi & Jordan Levy & Victoria Delibasic & Laura E. Davis & Alyson L. Mahar & Elmira Amirazodi & Craig C. Earle & Julie Hallet & Ahmed Hammad & Rajan Shah & Nicole Mittmann & Natalie G. Co, 2021. "The cost of chemotherapy administration: a systematic review and meta-analysis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(4), pages 605-620, June.
    17. Shadi Shafighi & Agnieszka Geras & Barbara Jurzysta & Alireza Sahaf Naeini & Igor Filipiuk & Alicja Ra̧czkowska & Hosein Toosi & Łukasz Koperski & Kim Thrane & Camilla Engblom & Jeff E. Mold & Xinsong, 2024. "Integrative spatial and genomic analysis of tumor heterogeneity with Tumoroscope," Nature Communications, Nature, vol. 15(1), pages 1-16, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0250634. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.